New report calls for collective action to fight ‘silent pandemic' of Asia's growing antimicrobial resistance
In Asia Pacific, related costs are projected to reach up to US$700 billion by 2050. However, timely investment could generate between US$10 billion and US$15 billion in annual healthcare savings.
A new report by Temasek Trust initiatives calls for more funding to tackle antimicrobial resistance in Asia (AMR), which could become the leading cause of death by 2050. The report, released May 5, outlines four key areas where funders can drive meaningful impact - from education and prevention to surveillance and treatment.
"Antimicrobial resistance is on track to become the deadliest health threat facing humanity. But with urgent action and targeted finance, over 100 million deaths could be prevented by 2050," reads the report by the Centre for Impact Investing and Practices (CIIP) and the World Economic Forum's GAEA (Giving to Amplify Earth Action) initiative, supported by the Philanthropy Asia Alliance (PAA).
Rising temperatures and extreme weather events are accelerating bacterial growth and disease transmission, while disrupting healthcare and immunisation services, say the report's authors. Climate-related pressures are also driving the increased use of antimicrobials in livestock and crops, contaminating freshwater sources and fuelling drug resistance, they add.
In Asia Pacific, AMR-related costs are projected to reach up to US$700 billion by 2050, accounting for up to 1% of the region's GDP. However, timely investment in AMR solutions could generate between US$10 billion and US$15 billion in annual healthcare savings, and cut the region's annual socioeconomic costs by up to US$40 billion within the next decade, claim the authors.
The 52-page report, titled "Targeted Action and Financing the Fight Against Antimicrobial Resistance in Asia", draws on insights from 15 case studies and examples of funding mechanisms, along with contributions from 26 organisations.
New therapeutics, such as drugs and vaccines, can take 10 to 15 years to develop and launch to market. Hence, the authors call for immediate and practical interventions to curb resistance today and pave the way for long-term solutions.
The report proposes interventions in four areas:
Educate: Improving knowledge and behaviour by strengthening awareness of AMR among clinicians, patients and farmers; emphasising the importance of avoiding the overuse or abuse of antimicrobials; as well as introducing strategies to prevent infections in the first place.
Prevent: Strengthening health systems and services by boosting preventive measures such as improving diagnostic capabilities and investing in better water, sanitation and hygiene measures.
Monitor: Enhancing regional surveillance, and data collection and sharing between actors, especially in lower-income countries.
Treat: Investing in research and development for new antimicrobials, and increasing access to novel and essential medicines.
Private funders, impact investors and philanthropists have a vital role to play in closing critical gaps, say the authors, particularly in late-stage drug development, where funding is scarce.
By pooling resources, funders can help bring life-saving treatments to market, strengthen the antibiotic pipeline, and build more sustainable and widespread access to essential medicines.
PAA CEO Shaun Seow says the report is a catalyst for deeper involvement from all sectors - philanthropic, public and private. "It highlights the scale of the AMR threat and the opportunity for collective action. We are encouraged by the ongoing work of organisations - including PAA members like the Gates Foundation, Wellcome Trust and Novo Nordisk Foundation - in driving AMR research and greater access to affordable solutions. Now is the time for more partners to come together, pool resources and support high-impact solutions that safeguard health and resilience across Asia and beyond."
Infographic: CIIP, GAEA, PAA
See Also:
Click here to stay updated with the Latest Business & Investment News in Singapore
'Green revolution' needed to solve issues like food systems and nutrition, says President Tharman
Trump administration will 'come around' on importance of partnerships: Bill Gates
WEF, GenZero launch Green Fuel Forward initiative to scale sustainable aviation fuel demand in APAC
Read more stories about where the money flows, and analysis of the biggest market stories from Singapore and around the World
Get in-depth insights from our expert contributors, and dive into financial and economic trends
Follow the market issue situation with our daily updates
Or want more Lifestyle and Passion stories? Click here
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
United States Diabetes Devices and Therapeutics Market Investment Opportunities Report 2025
The U.S. diabetes market is projected to grow at a CAGR of 7.2% from 2025-2029, reaching $39.33 billion. Key trends include real-time monitoring adoption, digital health integration, advanced delivery systems, and supportive regulatory frameworks. The report provides a data-centric analysis of market dynamics and opportunities. U.S. Diabetes Devices and Therapeutics Market Dublin, June 20, 2025 (GLOBE NEWSWIRE) -- The "United States Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update" report has been added to diabetes market in United States is expected to grow by 8.4% on annual basis to reach US$27.62 billion in diabetes market in the country has experienced robust growth during 2020-2024, achieving a CAGR of 9.1%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 7.2% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 25.47 billion to approximately USD 39.33 billion. The U.S. diabetes devices and therapeutics market is undergoing significant shifts with real-time monitoring, digital integration, advanced delivery systems, and evolving regulatory support. These trends will intensify over the next 2-4 years, shaping clinical practices and reimbursement structures while emphasizing data integration and precise patient management. The U.S. diabetes devices and therapeutics market is characterized by a mix of established players and new entrants. Strategic partnerships, acquisitions, and the integration of digital health solutions are reshaping competitive dynamics. In the coming years, market consolidation and targeted innovation are expected to further define the competitive environment, influencing product offerings and patient management Adoption of Real-Time Glucose Monitoring U.S. healthcare providers increasingly use continuous glucose monitoring (CGM) systems to track patient glucose levels in real-time. Large healthcare networks have adopted CGM systems to support outpatient diabetes management. Recent publications indicate improvements in insurance reimbursement policies and favorable regulatory reviews. Enhanced clinical data on the reliability of CGM systems reinforces their use in routine diabetes care. Adoption is expected to increase, driven by wider coverage and enhanced device integration with electronic health records. The trend will likely intensify as more clinical studies validate the benefits of real-time monitoring in reducing long-term complications. Integrate Digital Health Solutions into Diabetes Management U.S. providers are integrating device data with telehealth platforms and remote patient monitoring systems for diabetes management. Examples include healthcare systems deploying centralized digital dashboards to monitor patient metrics remotely. Recent industry reports highlight a shift in healthcare delivery models that suggests a push toward digital transformation in chronic disease management. Insurance models increasingly support telehealth consultations and remote monitoring, aligning with broader medtech trends. The integration of digital platforms is expected to grow, promoting data-driven decision-making and enhancing care coordination. This trend will likely intensify, leading to a more efficient tracking of treatment adherence and patient outcomes. Advance Therapeutic Delivery Systems The market is witnessing the emergence of devices that support precise therapeutic delivery, such as smart insulin pens. U.S. manufacturers are introducing systems for accurate dosing and treatment adherence monitoring. Technological advancements in device miniaturization and data analytics are facilitating the development of these delivery systems. Recent healthcare publications note a rising focus on improving patient safety and treatment precision in diabetes care. Market penetration of smart delivery systems is expected to grow, influenced by evolving clinical practice guidelines and supportive reimbursement frameworks. This trend will intensify as precision therapy becomes a central focus in diabetes management. Regulatory and Reimbursement Frameworks Recent changes in FDA and CMS policies support integrating digital tools in diabetes care. Updated guidelines and expanded reimbursement criteria for digital health applications evidence these regulatory adjustments. Broader healthcare policy initiatives for cost containment and improved patient outcomes drive these regulatory changes. Publications from the past year highlight a response to the increased demand for remote monitoring and digital therapeutics. Regulatory support is expected to maintain momentum, enabling continued investment in digital health and advanced therapeutics. The framework will further intensify market adoption of compliant and data-integrated devices. Current Market ConditionsThe market comprises established manufacturers and emerging firms. A diverse portfolio of devices and therapeutics is present, ranging from established CGM systems to new smart delivery devices. Assess Key Competitors and Emerging Entrants Major companies, such as large medical device manufacturers and specialized diabetes care firms, hold significant market share. Established firms maintain comprehensive product portfolios covering both devices and therapeutics. New market entrants focus on integrating digital health solutions with diabetes management systems. These entrants bring targeted innovations, complementing the existing product mix in the U.S. market. Examine Strategic Partnerships and Corporate Activities Recent publications document acquisitions of smaller digital health companies by established device manufacturers. Strategic partnerships have been initiated between healthcare systems and technology firms to expand remote monitoring capabilities. The market shows signs of consolidation driven by competitive pressures and regulatory incentives. Collaborative efforts are aimed at enhancing integrated care delivery and data analytics capabilities. Future Competitive Dynamics Continued consolidation and strategic alliances are expected as established players seek to enhance their technological offerings. New entrants with digital health expertise will likely drive niche innovations, altering competitive positioning. Over the next 2-4 years, the competitive landscape will likely evolve with intensified competition and targeted market consolidation. Companies will increasingly leverage partnerships to improve patient data integration and therapeutic outcomes. Key Attributes: Report Attribute Details No. of Pages 50 Forecast Period 2025 - 2029 Estimated Market Value (USD) in 2025 $29.83 Billion Forecasted Market Value (USD) by 2029 $39.33 Billion Compound Annual Growth Rate 7.2% Regions Covered United States ScopeDiabetes Devices and Therapeutics Market Share by Category Diagnosis and Monitoring Devices Therapeutics Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices Blood Glucose Monitoring Devices Insulin Delivery Devices Diabetes Management and Mobile Applications Artificial Pancreas Devices Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices Self-Monitoring Blood Glucose Devices Continuous Blood Glucose Monitoring Devices Test Strips Lancets Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices Insulin Pumps Insulin Pens Insulin Syringes Diabetes Devices and Therapeutics Market Share by Therapeutics Oral Anti-Diabetic Drugs Insulin Non-Insulin Injectable Drugs Combination Drugs Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs Alpha-Glucosidase Inhibitors DPP-4 Inhibitors SGLT-2 Inhibitors Diabetes Devices and Therapeutics Market Share by Insulin Basal or Long-Acting Bolus or Fast-Acting Traditional Human Insulin Drugs Insulin Biosimilars Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs GLP-1 Receptor Agonists Amylin Analogue Diabetes Devices and Therapeutics Market Share by Combination Drugs Combination Insulin Oral Combination Diabetes Devices and Therapeutics Market Share by Route of Administration Subcutaneous Intravenous Others Diabetes Devices and Therapeutics Market Share by Type of Diabetes Type 1 Diabetes Type 2 Diabetes Diabetes Devices and Therapeutics Market Share by Distribution Channels Online Pharmacies Hospital Pharmacies Retail Pharmacies Diabetes Devices and Therapeutics Market Share by End User Hospitals Diabetes Clinics Homecare For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Diabetes Devices and Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
3 days ago
- Yahoo
Dental Implants Market worth US$18.79 billion by 2030 with 8.4% CAGR
Delray Beach, FL, June 19, 2025 (GLOBE NEWSWIRE) -- The global dental implants market, valued at US$11.61 billion in 2024, stood at US$12.57 billion in 2025 and is projected to advance at a resilient CAGR of 8.4% from 2025 to 2030, culminating in a forecasted valuation of US$18.79 billion by the end of the period. Several factors are driving the global market for dental implants and dental prosthetics, including an uptick in dental infections, a growing patient population, and an increase in dental issues like periodontitis and cavities. The market is also benefiting from heightened awareness of oral health, a rising interest in cosmetic dentistry, and better access to dental care, particularly in developing countries. Challenges such as high treatment costs, limited insurance coverage, and financial constraints for low-income individuals are affecting the market. Additionally, strict product approval procedures and a shortage of skilled dentists may slow down market growth. However, the market is anticipated to keep growing in the future, driven by rising sugar consumption and an aging global population, which both contribute to worsening dental health issues. Download PDF Brochure: Browse in-depth TOC on 'Dental Implants Market'522 - Tables65 - Figures438 - Pages By Based on design, tapered dental implants held the largest share in tapered dental implants, by design in 2024. They are due to the several advantages it holds over the parallel-walled dental implants. By creating a wedge effect during insertion, the tapered shape improves initial stability by gently compressing the surrounding bone. Patients with weak or soft bones and those with little space between tooth roots can particularly benefit from this feature. They can handle immediate loading and are perfect for placing implants right away after tooth extraction, which shortens the healing period and minimizes the need for several interventions. Tapered implants are anticipated to contribute significantly to market expansion considering these advantages. By Based on type, The dental implants market is divided into root-form dental implants and plate-form dental implants. Factors such as their close resemblance to the structure and function of natural tooth roots provide several benefits for replacing lost teeth, which is why root-form dental implants are widely used in the market for dental implants. Also called Endosteal dental implant, it allows for natural-looking restorations due to the buried nature of the implant and predictable emergence profile and it stimulates bone growth around the implant, preventing bone resorption after tooth loss. These implants are highly versatile and effective in holding either a single tooth or multiple artificial teeth, thereby providing a stable foundation for crowns, bridges, or dentures. By Based on dentures, Complete dentures are anticipated to grow at higher CAGR than partial dentures in the next forecast period as they are becoming more popular as the go-to option for those who have lost all their teeth because of decay, gum disease, or trauma. Their cost and ability to restore essential activities like chewing, boost self-confidence, and improve facial beauty by minimizing sagging are the primary factors driving their expansion. There are two types of dentures available — conventional dentures, which are fitted after the gums have healed, and instant dentures, which are implanted immediately following a tooth extraction. Their non-invasive nature, shorter implantation time, and ease of modification for enhanced comfort or additional tooth loss all support their future market growth. By facility type, dental clinics and hospitals have the biggest market share for dental prosthetics market for a variety of reasons. Their access to state-of-the-art imaging and surgical equipment allows them to precisely handle challenging prosthetic cases, including customized solutions. Their extensive availability and capacity to treat a huge number of patients., presence of trained professionals like prosthodontists and oral surgeons further enhances their ability to provide excellent prosthesis care. Furthermore, their established reputation and patient confidence are quite important because consumers like to choose firms that are well-known and respectable. Their ability to offer a variety of services under one roof, such as consultations and follow-up care, further strengthens their competitive edge in the dental prosthetics sector. By geography, the six main regions that make up the global market for dental implants and dental prosthetics are North America, Europe, Asia Pacific, Latin America, the Middle East and Africa, and the GCC Countries. Because of its sophisticated healthcare systems, significant healthcare investment, and most importantly, the presence of important industry players, Europe is expected to be the largest regional market for dental implants and prosthetics during the forecast period. The region's residents enjoy a high standard of living, which raises awareness of dental health and increases demand for restorative and cosmetic dental operations, such as prosthetics and implants. Implants and prosthetics are becoming more widely available and effective due to local businesses' innovations in materials, design, and surgical procedures, while established European nations are actively engaged in the development and adoption of cutting-edge dental technologies. Request Sample Pages : The prominent players in the global dental implants and dental prosthetics market are Institut Straumann AG (Switzerland), Envista (US), Dentsply Sirona (US), Henry Schein, Inc. (US), Osstem Implant Co., Ltd. (South Korea), Solventum (US), ZimVie Inc. (US), Glidewell (US), Ivoclar Vivadent (Liechtenstein), Avinent Science and Technology (Spain), Bicon (US), Adin Dental Implant Systems, Ltd. (Israel), Dio Implant Co., Ltd. (South Korea), Thommen Medical AG (Switzerland), Southern Implants (South Africa), Keystone Dental Inc. (US), BEGO GmbH & Co. KG (Germany), SDI Dental Implants (Germany), Advin Health Care (India), Bioline Dental Implants (Germany), DENTAURUM GmbH & Co. KG (Germany), MEGA'GEN IMPLANT CO.,LTD (South Korea), Sweden & Martina S.p.A. (Italy), Medigma Biomedical GmbH (Germany), and LYRA ETK (France). Institut Straumann AG (Switzerland): accounted for the largest share of the global dental implants and dental prosthetics market in 2024. It operates in three key segments: Implant Solutions, Restorative Solutions, and Others. Through its implant solutions segment, the company provides dental implants and dental prosthetics. Implants, prostheses, biomaterials, and digital solutions are among the company's offerings to dentists and dental labs. Straumann provides a diverse selection of dental implant systems for a variety of clinical scenarios and patient demands, including iconic products like the BLX, TLX, and PURE implants. The company also provides a wide range of prosthetic solutions such as crowns, bridges, dentures, and implant-supported prosthetics made of titanium, zirconia, and PEEK. The company has significant presence in North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Envista (US): accounted for second largest share of the global dental implants and dental prosthetics market in 2024. The company's offer a wide range of dental equipment and consumables, including dental implants, prosthetics, imaging systems, endodontic tools, restorative materials, and infection prevention products. Envista operates in the dental implants segment under Nobel Biocare, Implant Direct and Alpha-Bio Tec brands. The company has a broad global reach, with its products sold over 120 countries. Envista separated from Danaher Corporation (US) in 2019 as an independent company to focus solely on dental solutions. Henry Schein, Inc. (US): accounted for third largest share of the global dental implants and dental prosthetics market in 2024. Henry Schein, Inc. has built a strong foothold in the global dental implants market by leveraging its vast healthcare distribution network and strategic acquisitions. The company operates through two core segments: Health Care Distribution (which includes Dental and Medical) and Technology & Value-added Services. Within the Health Care Distribution segment, its dental division specialises in dental implants and prosthetics. Henry Schein has maintained a strong position in the global dental implants market, driven by strategic investments and partnerships within its Global Oral Reconstruction Group. This group includes Camlog, BioHorizons, and Medentis Medical, each playing a key role in expanding Henry Schein's comprehensive portfolio of dental implant solutions and strengthening its market presence. For more information, Inquire Now! Related Reports: Dental Equipment Market Dental Consumables Market Dental Bone Graft Substitute Market Dental Laboratories Market Dental Soft-Tissue Regeneration Market Get access to the latest updates on Dental Implants and Prosthetics Companies and Dental Implants and Prosthetics Market Size CONTACT: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445, USA: +1-888-600-6441 Email: sales@ Visit Our Website: in to access your portfolio
Yahoo
3 days ago
- Yahoo
Human Papillomavirus (HPV) Vaccines Strategic Business Research Report 2024-2025 & 2030 - Rising Global Awareness of HPV-Linked Cervical and Oropharyngeal Cancers Drives Preventive Vaccination Uptake
The global Human Papillomavirus (HPV) Vaccines market, valued at USD 5.5 billion in 2024, is anticipated to grow to USD 9.7 billion by 2030 at a CAGR of 9.9%. This report offers comprehensive analysis of market trends and growth drivers, providing vital insights for businesses. Key highlights include the evolution of vaccine formulations, such as nonavalent vaccines targeting multiple HPV strains, which are crucial in preventing HPV-related cancers globally. Strategic vaccination programs and improved distribution strategies are driving market expansion, particularly in emerging economies. Despite barriers like misinformation and hesitancy, increased public awareness and partnerships with organizations like Gavi are expected to enhance uptake, especially in high-burden regions. The report also assesses the impact of global tariff developments on the HPV vaccines market. Human Papillomavirus (HPV) Vaccines Market Dublin, June 19, 2025 (GLOBE NEWSWIRE) -- The "Human Papillomavirus (HPV) Vaccines - Global Strategic Business Report" report has been added to global market for Human Papillomavirus (HPV) Vaccines was estimated at US$5.5 Billion in 2024 and is projected to reach US$9.7 Billion by 2030, growing at a CAGR of 9.9% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Human Papillomavirus (HPV) Vaccines market. Human papillomavirus (HPV) vaccines play a central role in the prevention of HPV-related cancers, including cervical, oropharyngeal, anal, and genital cancers. With over 200 types of HPV identified and high-risk strains such as HPV-16 and HPV-18 accounting for the majority of cervical cancer cases, widespread immunization is viewed as a cornerstone of global cancer prevention strategies. These vaccines stimulate the immune system to develop antibodies against targeted viral strains, offering long-term protection against persistent infections and precancerous lesions. The Growth in the HPV Vaccines Market Is Driven by Several is driven by increasing global efforts to prevent HPV-related cancers, expansion of immunization programs, and the availability of broad-spectrum vaccine formulations. Rising public health investment in women's health and cancer prevention, along with WHO's cervical cancer elimination strategy, is catalyzing demand. The inclusion of boys in vaccination programs and growing incidence of HPV-linked head and neck cancers are further expanding the addressable progress in vaccine efficacy, long-term protection data, and potential single-dose regimens is supporting broader implementation. Additionally, partnerships between governments, vaccine developers, and health organizations are enhancing procurement, education, and infrastructure especially in emerging markets. Digital health platforms and mHealth campaigns are also improving outreach and record tracking, increasing vaccine uptake. Collectively, these trends are reinforcing HPV vaccines as a critical tool in global disease prevention and a dynamic segment within the broader vaccines Are Vaccine Formulations and Distribution Strategies Evolving?HPV vaccines have progressed from bivalent formulations (targeting HPV-16 and 18) to quadrivalent (adding protection against HPV-6 and 11) and now to nonavalent vaccines, which protect against nine HPV strains, including those responsible for up to 90% of cervical cancers. These broader-spectrum vaccines offer greater coverage and are expected to dominate future procurement and immunization programs. Continuous innovation in recombinant vaccine production and adjuvant systems is enhancing immune response and duration of is being optimized through school-based vaccination programs, gender-neutral campaigns, and integration with national childhood immunization schedules. Advances in cold-chain infrastructure, coupled with partnerships between governments, NGOs, and vaccine manufacturers, are improving access in low- and middle-income countries. Single-dose regimens are also under investigation as a cost-effective and logistically simpler alternative, with promising results that may reshape vaccination protocol and broaden global Is Uptake Increasing and What Barriers Remain?Vaccination uptake is rising in North America, Europe, and parts of Asia-Pacific where public awareness, healthcare infrastructure, and policy support are strong. Gender-neutral vaccination strategies are gaining traction, particularly in countries prioritizing the prevention of head and neck cancers linked to HPV in males. Latin America and Sub-Saharan Africa, despite high HPV burden, still face challenges including supply limitations, healthcare access gaps, and cultural include misinformation, vaccine hesitancy, and inconsistent public health messaging, particularly in conservative or resource-constrained regions. Limited adult vaccination programs and affordability issues also hamper broader market penetration. However, partnerships with organizations such as Gavi, the Vaccine Alliance, are actively addressing supply inequities and financial barriers through tiered pricing and donor-funded initiatives. As these issues are mitigated, market growth is expected to accelerate, particularly in high-burden Insights: Market Growth: Understand the significant growth trajectory of the Tetravalent segment, which is expected to reach US$5.8 Billion by 2030 with a CAGR of a 9.5%. The Nonavalent segment is also set to grow at 11.3% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $1.5 Billion in 2024, and China, forecasted to grow at an impressive 13.4% CAGR to reach $2.0 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Barinthus Biotherapeutics, Bharat Biotech, BioNTech SE, CanSino Biologics Inc., and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include: Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs. Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015. Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends. Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape. Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players. Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities. Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage. Key Attributes: Report Attribute Details No. of Pages 279 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $5.5 Billion Forecasted Market Value (USD) by 2030 $9.7 Billion Compound Annual Growth Rate 9.9% Regions Covered Global MARKET OVERVIEW Influencer Market Insights World Market Trajectories Tariff Impact on Global Supply Chain Patterns Human Papillomavirus (HPV) Vaccines - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Rising Global Awareness of HPV-Linked Cervical and Oropharyngeal Cancers Drives Preventive Vaccination Uptake Inclusion of HPV Vaccines in National Immunization Programs Expands Coverage Across Adolescents and Young Adults WHO and GAVI Support for HPV Vaccine Rollout in Low-Income Countries Strengthens Public Health Impact Expansion of Gender-Neutral Vaccination Policies Fuels Demand Across Male and Female Populations Technological Advancements in Vaccine Formulations Improve Long-Term Efficacy and Broaden Strain Coverage Increased School-Based Immunization Drives High Compliance Rates in Developed and Emerging Regions Public-Private Partnerships and Awareness Campaigns Boost Community-Level Vaccine Acceptance Improved Cold Chain Infrastructure and Global Procurement Facilitate Distribution to Remote Areas Rising Incidence of HPV-Associated Head and Neck Cancers Spurs Broader Advocacy for Adult Vaccination Growing Market Entry of Biosimilar and Region-Specific HPV Vaccines Enhances Accessibility and Affordability FOCUS ON SELECT PLAYERS Barinthus Biotherapeutics Bharat Biotech BioNTech SE CanSino Biologics Inc. GlaxoSmithKline plc Inovio Pharmaceuticals Johnson & Johnson Merck & Co., Inc. Moderna, Inc. Novavax, Inc. Pfizer Inc. Sanofi S.A. Serum Institute of India Sinovac Biotech Ltd. Takeda Pharmaceutical Company Valneva SE Vaxart, Inc. Walvax Biotechnology Co., Ltd. Wantai BioPharm Xiamen Innovax Biotech Co., Ltd. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Human Papillomavirus (HPV) Vaccines Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
